Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
Date:11/1/2010

SEATTLE, Nov. 1, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for Pixuvri® (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). The application submission follows a positive opinion from the EMA's Pediatric Committee (the "PDCO"), where PDCO agreed to CTI's Pediatric Investigation Plan ("PIP") for Pixuvri.

"This is an important milestone for CTI, and underscores our commitment to making pixantrone available to patients who currently have no approved or effective therapies for this life threatening disease," said James A. Bianco, M.D., CEO of CTI. "We appreciate the efforts of all the people who made the MAA submission possible, especially the investigators and patients who participated in our clinical trial."  

"PIX301 was not only the first and only randomized trial in this patient population, it was also the largest study ever conducted for patients with multiply relapsed and refractory aggressive NHL. The positive results of this trial are among the most effective ever reported in this group of patients," noted Ruth Pettengell, M.D., of St. George's Hospital, University of London, the principal investigator on the study. "The robustness of the drug's effect in prolonging progression free survival irrespective of risk factors lends to the strength and credibility of the clinical benefit provided to patients in the trial. Currently there are no approved drugs available to patients today as such pixantrone will be a valuable new addition to offer these patients a new hope for controlling their disease."

Pixantrone was granted orphan drug status by the EMA for the treatment of diffuse large B-cell lymphoma (DLBCL). CTI expects that the EMA will make a determination regarding the ac
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... OREM, Utah , May 22, 2013  Aribex, ... handheld X-ray system, today introduced a new color option, ... into the U.S. dental and veterinary markets. The popular ... released last month will continue to be available and ... equipment dealers. (Photo: http://photos.prnewswire.com/prnh/20130522/CL19573 ) ...
(Date:5/22/2013)... Conn. , May 22, 2013 /PRNewswire-iReach/ -- ... stay aligned with the latest trends and events, ... that can predict where an industry is headed ... evolve. (Photo: http://photos.prnewswire.com/prnh/20130522/CG19099 ) ... partnership with market research publisher GlobalData, offer decision ...
(Date:5/22/2013)... 22, 2013  The Leukemia & Lymphoma Society (LLS) ... Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, ... a Phase I clinical trial for a novel fusion ... many patients with indolent lymphomas who do not respond ... protein, IGN002, is a new class of biotherapeutics produced ...
Breaking Medicine Technology:Aribex Unveils New Color of NOMAD Pro 2 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4
... 2011 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Executive Officer of Neurocrine Biosciences, will be presenting at ... New York.    The live presentation takes place ... Time / 8:00 a.m. Pacific Time.  The presentation will ...
... Nov. 23, 2011 Dune Medical Devices, Inc. today ... the 23rd Annual Piper Jaffray Healthcare Conference and will ... PM on Wednesday, November 30, 2011. The ... & 30, 2011 at the New York Palace Hotel, ...
Cached Medicine Technology:
(Date:5/23/2013)... 2013 911 Signal USA is attending the ... on May 22 and run through May 24, 2013. , ... the company's emergency vehicle lights and sirens, 911 ... Charger at the expo. , The Charger has been equipped ... and can be seen by visiting 911 Signal USA during ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 The surging ... consumers, however cutting through marketing claims to compare mattresses ... The Sleepy Shopper, a bed blog , offers shoppers ... leading types in their latest article. , Titled “ ... ”, this article guides readers through the basics of ...
(Date:5/22/2013)... Singapore (PRWEB) May 23, 2013 The Yoga of ... who lived a thousand years ago. This is the oldest ... leaves). , Lady Niguma was the partner of renowned Indian ... first known series specifically designed by a female yoga master. ... who in turn passed it on through a long lineage to ...
(Date:5/22/2013)... May 22, 2013 Jury deliberations are now ... involving a da Vinci lawsuit, Bernstein Liebhard LLP ... of a man who allegedly died of da Vinci surgery ... million in damages from Intuitive Surgical, Inc. Among other ... program for the da Vinci Surgical System in its efforts ...
(Date:5/22/2013)... Amy Norton HealthDay Reporter , , WEDNESDAY, May ... with athlete,s foot knows there is something about feet ... the first detailed "map" of the fungal groups that ... feet are the hottest neighborhood. It,s no secret ... such as bacteria, viruses and fungi, both outside and ...
Breaking Medicine News(10 mins):Health News:911 Signal USA Attends the 2013 Southwest Police Fleet Expo 2Health News:Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands 2Health News:Popular Yoga DVD, Lady Niguma Yoga Released for Sale Online 2Health News:Popular Yoga DVD, Lady Niguma Yoga Released for Sale Online 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3
... with some devices, research shows , THURSDAY, May 27 (HealthDay ... year-round glow are dramatically increasing their risk for developing melanoma, ... In fact, the more you tan and the longer you ... found the risk of melanoma was 74 percent higher in ...
... state-of-the-art heart pump recently approved for use in end-stage cardiac ... earlier model of the device, according to researchers at Henry ... assist device, the newest version of the HeartMate ,is much ... synthetic ruby bearings, lubricated by the blood itself, to continually ...
... ... trust, proudly announces the opening of a new technology solutions office in Ahwatukee to better ... 10% off all business IT and Phoenix computer repair services or free website hosting for ... ...
... ... ... Tahitian Noni International (TNI) has announced that Eric Bennett, bass singer for the ... with being a part of the “Favorite Male Quartet” awarded by Singing News fans, Bennett ...
... ... and Ecomfort Products. The Online Retailer continues to add Bedding and Bedroom Furniture choices ... Prices. , ... May 27, 2010 -- Home and Bedroom has just added Simmons Beautyrest Mattresses ...
... ... to be featured on the award-winning educational television program, “Insights” with Hugh Downs, as ... , ... May 27, 2010 -- Emerald Express International , a visionary company dedicated to ...
Cached Medicine News:Health News:Tanning Beds Can Greatly Boost Melanoma Risk 2Health News:Tanning Beds Can Greatly Boost Melanoma Risk 3Health News:Henry Ford Hospital study: Fewer infections with new heart-pump implant 2Health News:my PC Techs Opens New Technology Solutions Office in Ahwatukee 2Health News:Eric Bennett Is Singing a New Tune With Tahitian Noni International 2Health News:Home and Bedroom Adds Simmons Beautyrest Mattresses to Help Customers Sleep Well 2Health News:Emerald Express International to be Featured on ‘Insights' with Hugh Downs this Spring in a Segment that Spotlights Glutathione and Anti-Aging 2Health News:Emerald Express International to be Featured on ‘Insights' with Hugh Downs this Spring in a Segment that Spotlights Glutathione and Anti-Aging 3
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 4.0 inches....
Angled 45 degree shafts 10 mm tying platform. Serrated handle with dull finish. Overall length 3.3 inches....
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Angl...
Medicine Products: